

Perkins Coie Advises Pacira BioSciences, Inc. in \$402-Million Convertible Note Offering

DENVER (July 7, 2020)—Perkins Coie represented New Jersey-based pharmaceuticals company, Pacira Biosciences, Inc., in its \$402-million offering of convertible senior notes in a [private placement](#) pursuant to Rule 144A under the Securities Act of 1933.

The Firmwide Chair of Perkins Coie's Corporate Practice, Jason Day, led the firm's deal team which also included Denver-based partner Ned Prusse and counsel Jonathan Schulman, Seattle-based partner Eric DeJong, and associates Christopher Wassman and Cassandra Wetzel.

Pacira BioSciences is a top provider of regenerative health treatments and non-opioid pain management committed to improving and advancing outcomes for healthcare practitioners and their patients.

Perkins Coie is a leading global law firm, dedicated to helping the world's most innovative companies solve the legal and business challenges of tomorrow. Learn about our work and values [here](#).

Media Inquiries: Please email [Justin Cole](#), Head of Media Relations.

Contact



[Jason Day](#)

Partner

JDay@perkinscoie.com [303.291.2362](tel:303.291.2362)



Ned A. Prusse

Partner

NPrusse@perkinscoie.com [303.291.2374](tel:303.291.2374)



Jonathan S. Schulman

Partner

JSchulman@perkinscoie.com [303.291.2309](tel:303.291.2309)



Eric A. DeJong

Partner

EDeJong@perkinscoie.com [206.359.3793](tel:206.359.3793)



Christopher Wassman

Counsel

CWassman@perkinscoie.com [206.359.3807](tel:206.359.3807)

Explore more in

[Capital Markets](#)

Media inquiries